A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
The company will address these observations within the stipulated timeline
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
The academy has secured partnerships with 15 esteemed hospitals
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
Subscribe To Our Newsletter & Stay Updated
